CBLL Overview

CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its hardware is composed of disposable, flexible headbands and head caps (Wearables) and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals. EEG data captured by the recorder are interpreted by its proprietary AI-powered seizure detection algorithms, which monitor the patient’s EEG signal and support the clinician’s real-time assessment of seizure activity.

Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is29.67 USD with a low forecast of 29.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ceribell Inc revenue for the last quarter amounts to 26.49M USD, increased 29.30

Ceribell Inc. EPS for the last quarter amounts to -0.52 USD, increased 44.44

Ceribell Inc (CBLL) has 327 emplpoyees as of May 31 2026.

Today CBLL has the market capitalization of 700.04M USD.